EyePoint is downgraded from a speculative Strong Buy to a Hold following LUCIA’s failure, pending greater clarity on cash runway. Read more on EYPT stock here.
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
EyePoint stock is heading for its largest single-day percentage drop on record.
Detailed price information for Eyepoint Inc (EYPT-Q) from The Globe and Mail including charting and trades.
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,00
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.